Levi & Korsinsky announces the filing of a class action lawsuit in the USDC for the District of New Jersey on behalf of shareholders of Amicus Therapeutics, Inc. (“Amicus Therapeutics” or the “Company”) (NASDAQ: FOLD) who purchased shares between March 19, 2015 and October 1, 2015.
The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose that the United States Food and Drug Administration raised concerns about Amicus Therapeutics’ forthcoming new drug application for migalastat during their September 15, 2015 meeting. On October 2, 2015, Amicus Therapeutics revealed it would no longer be in a position to submit its NDA in the fourth quarter of 2015. Upon this news, shares of Amicus Therapeutics fell 54% to close at $6.39 per share. If you suffered a loss in Amicus Therapeutics you have until December 7, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.